Designing a better theranostic nanocarrier for cancer applications

Nanomedicine

Volumn 9, Issue 15, 2014, Pages 2371-2386

  Nguyen, Trinh ^a   Tekrony, Amy ^a   Yaehne, Kristin ^a   Cramb, David T ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

biological barriers; chorioallantoic membrane; exogenous and endogenous triggered drug release; protein corona; theranostic nanocarrier

Indexed keywords

GLYCOSIDASE; GOLD NANOPARTICLE; LIPOSOME; NANOCARRIER; PHOSPHOLIPASE; PROTEINASE; QUANTUM DOT; THERANOSTIC NANOCARRIER; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG CARRIER;

ANGIOGENESIS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CELL MEMBRANE; CIRCULATION TIME; CONTROLLED DRUG RELEASE; DRUG ACCUMULATION; ECHOGRAPHY; FLUORESCENCE ANALYSIS; HEAT; HEAT SENSITIVITY; HUMAN; HYDROPHILICITY; INTERNALIZATION; LIGHT EXPOSURE; LIPID BILAYER; LIPOSOMAL DELIVERY; MAGNETIC FIELD; MEMBRANE TRANSPORT; NANOENCAPSULATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATION REDUCTION POTENTIAL; PH; PHOTOACOUSTICS; RETICULOENDOTHELIAL SYSTEM; REVIEW; SURFACE CHARGE; ULTRASOUND; NEOPLASMS;

ANTINEOPLASTIC AGENTS; DRUG CARRIERS; HUMANS; LIPOSOMES; NEOPLASMS;

EID: 84912092075     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.14.110     Document Type: Review

References (92)

1. Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today 11(17-18), 812-818 (2006).
2. Feng SS. New-concept chemotherapy by nanoparticles of biodegradable polymers: where are we now? Nanomedicine 1(3), 297-309 (2006).
3. Clancy AA, Gregoriou Y, Yaehne K, Cramb DT. Measuring properties of nanoparticles in embryonic blood vessels: towards a physicochemical basis for nanotoxicity. Chem. Phys. Lett. 488(4-6), 99-111 (2010).
4. Heuff RF, Cramb DT, Marrocco M. Fluorescence correlation spectroscopy for diffusion of mobile quantum dots in dilute solutions. Chem. Phys. Lett. 454(4-6), 257-261 (2008).
5. Knop K, Hoogenboom R, Fischer D, Schubert US. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew. Chem. Int. Ed. Engl. 49(36), 6288-6308 (2010).
6. Blanco E, Hsiao A, Mann AP, Landry MG, Meric- Bernstam F, Ferrari M. Nanomedicine in cancer therapy: innovative trends and prospects. Cancer Sci. 102(7), 1247-1252 (2011).
7. Hubbell JA, Chilkoti A. Nanomaterials for drug delivery. Science 337(6092), 303-305 (2012).
8. Chen YC, Huang XC, Luo YL, Chang YC, Hsieh YZ, Hsu HY. Non-metallic nanomaterials in cancer theranostics: a review of silica- and carbon-based drug delivery systems. Sci. Technol. Adv. Mater. 14, 044407 (2013).
9. Cheng SH, Lee CH, Chen MC et al. Tri-functionalization of mesoporous silica nanoparticles for comprehensive cancer theranostics -the trio of imaging, targeting and therapy. J. Mater. Chem. 20(29), 6149-6157 (2010).
10. He QJ, Ma M, Wei CY, Shi JL. Mesoporous carbon@ silicon-silica nanotheranostics for synchronous delivery of insoluble drugs and luminescence imaging. Biomaterials 33(17), 4392-4402 (2012).
11. Zou P, Yu YK, Wang YA et al. Superparamagnetic iron oxide nanotheranostics for targeted cancer cell imaging and pH-dependent intracellular drug release. Mol. Pharm. 7(6), 1974-1984 (2010).
12. Liu P, Yue CX, Sheng ZH et al. Photosensitizer-conjugated redox-responsive dextran theranostic nanoparticles for nearinfrared cancer imaging and photodynamic therapy. Polymer Chem. 5(3), 874-881 (2014).
13. Lukianova-Hleb EY, Santiago C, Wagner DS, Hafner JH, Lapotko DO. Generation and detection of plasmonic nanobubbles in zebrafish. Nanotechnology 21(22), 225102 (2010).
14. Melancon MP, Lu W, Li C. Gold-based magneto/ optical nanostructures: challenges for in vivo applications in cancer diagnostics and therapy. Mater. Res. Bull. 34(6), 415-421 (2009).
15. Lukianova-Hleb EY, Hanna EY, Hafner JH, Lapotko DO. Tunable plasmonic nanobubbles for cell theranostics. Nanotechnology 21(8), 85102 (2010).
16. Crawley N, Thompson M. Theranostics in the growing field of personalized medicine: an analytical chemistry perspective. Anal. Chem. 86(1), 130-160 (2014).
17. Freitas RA Jr. The future of nanomedicine. Futurist 44(1), 21-22 (2010).
18. Sun DX. Nanotheranostics: integration of imaging and targeted drug delivery. Mol. Pharm. 7(6), 1879-1879 (2010).
19. Mura S, Couvreur P. Nanotheranostics for personalized medicine. Adv. Drug Deliv. Rev. 64(13), 1394-1416 (2012).
20. Baker M. The whole picture. Nature 463(7283), 977-980 (2010).
21. Langereis S, Geelen T, Grull H, Strijkers GJ, Nicolay K. Paramagnetic liposomes for molecular MRI and MRI-guided drug delivery. NMR Biomed. 26(7), 728-744 (2013).
22. Yoo D, Lee JH, Shin TH, Cheon J. Theranostic magnetic nanoparticles. Acc. Chem. Res. 44(10), 863-874 (2011).
23. Soundararajan A, Bao A, Phillips WT, Perez R, Goins BA. Re-186 liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model. Nucl. Med. Biol. 36(5), 515-524 (2009).
24. Hahn MA, Singh AK, Sharma P, Brown SC, Moudgil BM. Nanoparticles as contrast agents for in-vivo bioimaging: current status and future perspectives. Anal. Bioanal. Chem. 399(1), 3-27 (2011).
25. Ntziachristos V. Going deeper than microscopy: the optical imaging frontier in biology. Nat. Methods 7(8), 603-614 (2010).
26. Melancon MP, Stafford RJ, Li C. Challenges to effective cancer nanotheranostics. J. Control. Release 164(2), 177-182 (2012).
27. Olivo M, Ho CJH, Fu CY. Advances in fluorescence diagnosis to track footprints of cancer progression in vivo. Laser Photon. Rev. 7(5), 646-662 (2013).
28. Diou O, Tsapis N, Fattal E. Targeted nanotheranostics for personalized cancer therapy. Expert Opin. Drug Deliv. 9(12), 1475-1487 (2012).
29. Lukianova-Hleb EY, Lapotko DO. Nano-theranostics with plasmonic nanobubbles. IEEE J. Select. Top. Quantum Electron. 20(3), 7300412 (2014).
30. Li SH, Goins B, Zhang LJ, Bao AD. Novel multifunctional theranostic liposome drug delivery system: construction, characterization, and multimodality MR, near-infrared fluorescent, and nuclear imaging. Bioconjug. Chem. 23(6), 1322-1332 (2012).
31. Ke HT, Wang JR, Tong S et al. Gold nanoshelled liquid perfluorocarbon magnetic nanocapsules: a nanotheranostic platform for bimodal ultrasound/magnetic resonance imaging guided photothermal tumor ablation. Theranostics 4(1), 12-23 (2014).
32. Davis ME, Chen Z, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7(9), 771-782 (2008).
33. Gupta H, Aqil M, Khar RK, Ali A, Bhatnagar A, Mittal G. Biodegradable levofloxacin nanoparticles for sustained ocular drug delivery. J. Drug Target. 19(6), 409-417 (2011).
34. Petros RA, Desimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discov. 9(8), 615-627 (2010).
35. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 65(1-2), 271-284 (2000).
36. Casals E, Pfaller T, Duschl A, Oostingh GJ, Puntes V. Time evolution of the nanoparticle protein corona. ACS Nano 4(7), 3623-3632 (2010).
37. Nel AE, Maedler L, Velegol D et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat. Mater. 8(7), 543-557 (2009).
38. Kievit FM, Zhang MQ. Cancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers. Adv. Mater. 23(36), H217-H247 (2011).
39. Yokoe JI, Sakuragi S, Yamamoto K et al. Albuminconjugated PEG liposome enhances tumor distribution of liposomal doxorubicin in rats. Int. J. Pharm. 353(1-2), 28-34 (2008).
40. Hatakeyama S, Sugihara K, Shibata TK et al. Targeted drug delivery to tumor vasculature by a carbohydrate mimetic peptide. Proc. Natl Acad. Sci. USA 108(49), 19587-19592 (2011).
41. Ruoslahti E, Bhatia SN, Sailor MJ. Targeting of drugs and nanoparticles to tumors. J. Cell Biol. 188(6), 759-768 (2010).
42. Gou M, Men K, Shi H et al. Curcumin-loaded biodegradable polymeric micelles for colon cancer therapy in vitro and in vivo. Nanoscale 3(4), 1558-1567 (2011).
43. Champion JA, Mitragotri S. Role of target geometry in phagocytosis. Proc. Natl Acad. Sci. USA 103(13), 4930-4934 (2006).
44. Chen L, McCrate JM, Lee JCM, Li H. The role of surface charge on the uptake and biocompatibility of hydroxyapatite nanoparticles with osteoblast cells. Nanotechnology 22(10), 105708 (2011).
45. Gratton SEA, Ropp PA, Pohlhaus PD et al. The effect of particle design on cellular internalization pathways. Proc. Natl Acad. Sci. USA 105(33), 11613-11618 (2008).
46. Harush-Frenkel O, Rozentur E, Benita S, Altschuler Y. Surface charge of nanoparticles determines their endocytic and transcytotic pathway in polarized MDCK cells. Biomacromolecules 9(2), 435-443 (2008).
47. Lian T, Ho RJY. Trends and developments in liposome drug delivery systems. J. Pharm. Sci. 90(6), 667-680 (2001).
48. Ishida O, Maruyama K, Yanagie H, Eriguchi H, Iwatsuru M. Targeting chemotherapy to solid tumors with long-circulating thermosensitive liposomes and local hyperthermia. Jpn J. Cancer Res. 91(1), 118-126 (2000).
49. Yih TC, Al-Fandi M. Engineered nanoparticles as precise drug delivery systems. J. Cell. Biochem. 97(6), 1184-1190 (2006).
50. Sampathkumar K, Arulkumar S, Ramalingam M. Advances in stimuli responsive nanobiomaterials for cancer therapy. J. Biomed. Nanotechnol. 10, 367-382 (2014).
51. Al-Ahmady ZS, Al-Jamal WT, Bossche JV et al. Lipid-peptide vesicle nanoscale hybrids for triggered drug release by mild hyperthermia in vitro and in vivo. ACS Nano 6(10), 9335-9346 (2012).
52. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Deliv. Rev. 65(1), 36-48 (2013).
53. Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat. Mater. 12(11), 991-1003 (2013).
54. Needham D, Anyarambhatla G, Kong G, Dewhirst MW. A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res. 60(5), 1197-1201 (2000).
55. Mills JK, Needham D. Lysolipid incorporation in dipalmitoylphosphatidylcholine bilayer membranes enhances the ion permeability and drug release rates at the membrane phase transition. Biochim. Biophys. Acta 1716(2), 77-96 (2005).
56. Blenke EO, Mastrobattista E, Schiffelers RM. Strategies for triggered drug release from tumor targeted liposomes. Expert Opin. Drug Deliv. 10(10), 1399-1410 (2013).
57. Chen KJ, Liang HF, Chen HL et al. A thermoresponsive bubble-generating liposomal system for triggering localized extracellular drug delivery. ACS Nano 7(1), 438-446 (2013).
58. Babincová M, Imanec P, Altanerová V, Altaner, Babinec P. AC-magnetic field controlled drug release from magnetoliposomes: design of a method for site-specific chemotherapy. Bioelectrochemistry 55(1-2), 17-19 (2002).
59. Kulshrestha P, Gogoi M, Bahadur D, Banerjee R. In vitro application of paclitaxel loaded magnetoliposomes for combined chemotherapy and hyperthermia. Colloids Surf. B Biointerfaces 96, 1-7 (2012).
60. Bisby RH, Mead C, Morgan CC. Wavelength-programmed solute release from photosensitive liposomes. Biochem. Biophys. Res. Commun. 276(1), 169-173 (2000).
61. Thompson DH, Gerasimov OV, Wheeler JJ, Rui YJ, Anderson VC. Triggerable plasmalogen liposomes: omprovement of system efficiency. Biochim. Biophys. Acta 1279(1), 25-34 (1996).
62. Lin C-Y, Javadi M, Belnap DM, Barrow JR, Pitt WG. Ultrasound sensitive eLiposomes containing doxorubicin for drug targeting therapy. Nanomedicine 10(1), 67-76 (2014).
63. Schroeder A, Kost J, Barenholz Y. Ultrasound, liposomes, and drug delivery: principles for using ultrasound to control the release of drugs from liposomes. Chem. Phys. Lipids 162(1-2), 1-16 (2009).
64. Fattal E, Couvreur P, Dubernet C. 'Smart' delivery of antisense oligonucleotides by anionic pH-senstive liposomes. Adv. Drug Deliv. Rev. 56, 931-946 (2004).
65. Lee S-M, Nguyen ST. Smart nanoscale drug delivery platforms from stimuli-responsive polymers and liposomes. Macromolecules 46(23), 9169-9180 (2013).
66. Ong W, Yang YM, Cruciano AC, McCarley RL. Redoxtriggered contents release from liposomes. J. Am. Chem. Soc. 130(44), 14739-14744 (2008).
67. Davidsen J, Jorgensen K, Andresen TL, Mouritsen OG. Secreted phospholipase A2 as a new enzymatic trigger mechanism for localised liposomal drug release and absorption in diseased tissue. Biochim. Biophys. Acta 1609(1), 95-101 (2003).
68. Haque ME, Lentz BR. Roles of curvature and hydrophobic interstice energy in fusion: studies of lipid perturbant effects. Biochemistry 43(12), 3507-3517 (2004).
69. Mabrey S, Sturtevant JM. Incorporation of saturated fattyacids into phosohatidylcholine bilayers. Biochim. Biophys. Acta 486(3), 444-450 (1977).
70. Nguyen TT, Swift JL, Burger MC, Cramb DT. Effects of various small-molecule anesthetics on vesicle fusion: a study using two-photon fluorescence cross-correlation spectroscopy. J. Phys. Chem. B 113(30), 10357-10366 (2009).
71. Mondal S, Sarkar M. Non-steroidal anti-Inflammatory drug induced membrane fusion: concentration and temperature effects. J. Phys. Chem. B 113(51), 16323-16331 (2009).
72. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol. 7(11), 653-664 (2010).
73. Jain K. Advances in the field of nanooncology. BMC Med. 8, 83 (2010).
74. Kim BYS, Rutka JT, Chan WCW. Current concepts: nanomedicine. N. Engl. J. Med. 363(25), 2434-2443 (2010).
75. Krasnici S, Werner A, Eichhorn ME et al. Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels. Int. J. Cancer 105(4), 561-567 (2003).
76. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer-chemotherapy -mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res. 46(12), 6387-6392 (1986).
77. Sarsons CD, Tekrony A, Yaehne K, Childs S, Rinker KD, Cramb D. Testing nanoparticles for angiogenesis-related disease: charting the fastest route to the clinic. J. Biomed. Nanotechnol. 10, 1-36 (2014).
78. Rizzo V, Kim D, Duran WN, Defouw DO. Ontogeny of microvascular permeability to macromolecules in the chick chorioallantoic membrane during normal angiogenesis. Microvasc. Res. 49(1), 49-63 (1995).
79. Tufan AC, Lale Satiroglu-Tufan N. The chick embryo chorioallantoic membrane as a model system for the study of tumor angiogenesis, invasion and development of antiangiogenic agents. Curr. Cancer Drug Targets 5(4), 249-266 (2005).
80. Willey CD, Burleson TM, Zhai L, Anderson JC. The development of a chorioallantoic membrane-tumor xenograft model for tumor vascular targeting with radiation. Int. J. Radiat. Oncol. Biol. Phys. 78(3), S624-S625 (2010).
81. Murphy J. Transplantability of tissues to the embryo of foreign species: its bearing on questions of tissue specificity and tumor immunity. J. Exp. Med. 17(4), 482-493 (1913).
82. Grodzik M, Sawosz E, Wierzbicki M et al. Nanoparticles of carbon allotropes inhibit glioblastoma multiforme angiogenesis in ovo. Int. J. Nanomed. 6, 3041-3048 (2011).
83. Yaehne K, Tekrony A, Clancy A et al. Nanoparticle accumulation in angiogenic tissues: towards predictable pharmacokinetics. Small 9(18), 3118-3127 (2013).
84. Dreher MR, Liu WG, Michelich CR, Dewhirst MW, Yuan F, Chilkoti A. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J. Natl Cancer Inst. 98(5), 335-344 (2006).
85. Smith J, Fisher G, Waggoner A, Campbell P. The use of quantum dots for analysis of chick CAM vasculature. Microvasc. Res. 73(2), 75-83 (2007).
86. Lewis J, Destito G, Zijlstra A et al. Viral nanoparticles as tools for intravital vascular imaging. Nat. Med. 12(3), 354-360 (2006).
87. Sourabh S, Amber LA, Amy MW, Karin LL, John DL, Nicole FS. Increased tumor homing and tissue penetration of the filamentous plant viral nanoparticle potato virus X. Mol. Pharm. 10(1), 33-42 (2013).
88. Vargas A, Pegaz B, Debefve E et al. Improved photodynamic activity of porphyrin loaded into nanoparticles: an in vivo evaluation using chick embryos. Int. J. Pharm. 286(1-2), 131-145 (2004).
89. Vargas A, Lange N, Arvinte T, Cerny R, Gurny R, Delie F. Toward the understanding of the photodynamic activity of m-THPP encapsulated in PLGA nanoparticles: correlation between nanoparticle properties and in vivo activity. J. Drug Target. 17(8), 599-609 (2009).
90. Liu Y, Gao FP, Zhang D, Fan YS, Chen XG, Wang H. Molecular structural transformation regulated dynamic disordering of supramolecular vesicles as pH-responsive drug release systems. J. Control. Release 173, 140-147 (2014).
91. Ta T, Porter TM. Thermosensitive liposomes for localized delivery and triggered release of chemotherapy. J. Control. Release 169(1-2), 112-125 (2013).
92. Shimanouchi T, Kawasaki H, Fuse M, Umakoshi H, Kuboi R. Membrane fusion mediated by phospholipase C under endosomal pH conditions. Colloids Surf. B Biointerfaces 103, 75-83 (2013).